How does 7R8's PB Ratio compare to its peers?

7R8 is expensive based on its Price-To-Book Ratio (2.5x) compared to the peer average (1.9x).

How does 7R8's PB Ratio compare vs other companies in the DE Biotechs Industry?

7R8 is expensive based on its Price-To-Book Ratio (2.5x) compared to the European Biotechs industry average (2.4x).

What is 7R8's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 7R8's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 7R8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

7R8 (€13.4) is trading below our estimate of [[fair value]] (€27.8)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is less than 20% higher than the current share price.

Replimune Group (DB:7R8) - Stock Price, News & Analysis

7R8 Stock Overview

A clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. More details

7R8 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 51.8% below our estimate of its fair value

Revenue is forecast to grow 57.42% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Makes less than USD$1m in revenue ($0)

Significant insider selling over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

Replimune Group, Inc. Competitors

Formycon

XTRA:FYB

€857.2m

Biotest

XTRA:BIO3

€1.3b

Heidelberg Pharma

XTRA:HPHA

€105.8m

2invest

XTRA:2INV

€62.7m

Price History & Performance

Summary of all time highs, changes and price drops for Replimune Group
Historical stock prices
Current Share Price	US$13.40
52 Week High	US$15.00
52 Week Low	US$4.56
Beta	1.19
11 Month Change	21.82%
3 Month Change	45.65%
1 Year Change	30.10%
33 Year Change	-45.97%
5 Year Change	9.84%
Change since IPO	9.75%

Recent updates

Shareholder Returns

	7R8	DE Biotechs	DE Market
7D	31.4%	0.8%	0.8%
1Y	30.1%	-18.3%	8.6%

Return vs Industry: 7R8 exceeded the German Biotechs industry which returned -18.3% over the past year.

Return vs Market: 7R8 exceeded the German Market which returned 8.6% over the past year.

Price Volatility

Is 7R8's price volatile compared to industry and market?
7R8 volatility
7R8 Average Weekly Movement	14.5%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 7R8's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 7R8's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2015	331	Sush Patel	www.replimune.com

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors.

Replimune Group, Inc. Fundamentals Summary

How do Replimune Group's earnings and revenue compare to its market cap?
7R8 fundamental statistics
Market cap	€931.21m
Earnings (TTM)	-€201.63m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-4.5x

P/E Ratio

Is 7R8 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7R8 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$213.02m
Earnings	-US$213.02m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-3.11
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	11.9%

How did 7R8 perform over the long term?

See historical performance and comparison

7R8 Stock Overview

Rewards

Risk Analysis

Replimune Group, Inc. Competitors

XTRA:FYB

€857.2m

XTRA:BIO3

€1.3b

XTRA:HPHA

€105.8m

XTRA:2INV

€62.7m

Price History & Performance

Recent News & Updates

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Recent updates

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Executive Chairman recently sold €226k worth of stock

Replimune Group, Inc. Announces Management Changes

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

No longer forecast to breakeven

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

CEO & Director recently sold €298k worth of stock

No longer forecast to breakeven

Insufficient new directors

Replimune Group, Inc. Announces Executive Appointments

Now 23% undervalued

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune Group, Inc., Annual General Meeting, Sep 07, 2022

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 2000 Growth Index

Replimune Group, Inc. Announces the Resignation of Jason Rhodes from Its Board of Directors

Chief Commercial Officer recently sold €150k worth of stock

Replimune Group, Inc. Announces Updated Data from Completed Cohorts of the Phase 2 Part of the IGNYTE Clinical Trial in Non-Melanoma Skin Cancer (Nmsc) and Melanoma

Replimune Group, Inc. Announces Departure of Dr. Otello Stampacchia from its Board of Directors

Now 22% undervalued after recent price drop

Chief Medical Officer Andrea Pirzkall has left the company

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 3000E Index

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

Forecast to breakeven in 2026

Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma

New 90-day low: €30.40

Replimune Group, Inc. Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

New 90-day high: €41.20

Replimune Group Inc. Announces Poster Presentations at the SITC 2020 Annual Meeting and a Presentation at the SITC 2020 Annual Meeting Virtual Press Conference

New 90-day high: €36.20

Replimune Group, Inc. Appoints Tanya Lewis to its Board of Directors, Effective November 2, 2020

Replimune Group, Inc. Announces Initial Clinical Data of Rp2 and Updated Clinical Data of RP1

New 90-day high - €21.40

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Shareholder Returns

Price Volatility

About the Company

Replimune Group, Inc. Fundamentals Summary

0.0x

-4.5x

Earnings & Revenue